{"filings":[{"id":2272078,"accession_number":"0001213900-26-090115","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2026-08-14T20:20:32+00:00","items":["2.02","9.01"],"status":"ready","headline":"Corvex Q2 revenue $3.8M, net loss $12.8M; contracted ARR ~$22M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $3.8M vs $103K prior year; net loss $12.8M ($5.12/share) vs $3.2M loss.","Adjusted EBITDA -$3.2M; cash $21.7M; deferred revenue $3.7M.","Contracted annualized revenue on live compute ~$22M as of Aug 14, 2026.","Completed transfer of legacy healthcare assets to lender, extinguishing Bridge Loan, $2.5M gain.","Appointed CFO Chance Moreland, VP Michael Craig; added two board members; simplified capital structure."],"consensus_eps_estimate":null,"consensus_eps_actual":-8.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":4312000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1501117,"accession_number":"0001213900-26-076046","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2026-07-07T21:10:57+00:00","items":["8.01","3.02","5.02","5.03","5.07","9.01"],"status":"ready","headline":"Corvex appoints Seth Demsey co-CEO; preferred shares convert, common outstanding rises to 27.6M","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Seth Demsey appointed co-CEO alongside Jay Crystal effective July 1, 2026, following stockholder approval.","Stockholders approved conversion of Series C and D preferred into common; Series C auto-converted on July 7.","Series D holders converted 4,752,244 shares of common; total common outstanding now 27,635,745.","Remaining Series D convertible into 28,929,592 common shares; authorized Series D increased to 50,000 shares.","Stockholders also approved 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1290436,"accession_number":"0001213900-26-072420","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2026-06-26T14:26:32+00:00","items":["8.01"],"status":"ready","headline":"Corvex adjourns 2026 annual meeting to July 1; all proposals have overwhelming support","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting adjourned from June 26 to July 1, 2026, at 3:00 pm ET for administrative reasons.","Preliminary voting shows all proposals received overwhelming support; record date unchanged at April 28, 2026.","Company continues to solicit votes; stockholders urged to vote by June 30, 2026, 11:59 pm ET.","No changes to proposals or proxy statement; definitive proxy was filed June 5, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1067596,"accession_number":"0001213900-26-069066","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2026-06-16T13:22:11+00:00","items":["9.01"],"status":"ready","headline":"Corvex appoints Chance Moreland as CFO effective June 29, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Moreland joins from Morgan Stanley where he was Managing Director in Leveraged & Acquisition Finance.","Annual base salary of $425,000; eligible for annual performance bonus up to 100% of base salary.","Granted 523,211 RSUs (four-year annual vest) and 523,211 PSUs (max achievement) under 2026 PSU program.","J. Cogan will continue as CFO until Moreland's appointment on June 29, 2026.","Severance upon termination without cause or resignation for good reason includes 1x salary, prorated bonus, and accelerated equity vesting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":526757,"accession_number":"0001213900-26-059003","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2026-05-19T20:07:06+00:00","items":["2.02","9.01"],"status":"ready","headline":"Corvex Q1 revenue $510k, net loss $(5.1M) after OpCo acquisition; pro forma revenue $3.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Completed acquisition of Corvex OpCo on March 19, 2026; renamed from Movano to Corvex.","Q1'26 revenue $510k (incl. 12 days of OpCo) vs $206k in Q1'25; AI platform services contributed $475k.","Net loss $(5.1M) or $(3.13) per share vs $(5.2M) or $(5.35) per share; adjusted EBITDA loss $(1.6M) improved 67%.","Pro forma Q1'26: revenue $3.7M, net loss $(15.9M), adjusted EBITDA loss $(0.9M).","Cash $29.3M; deferred revenue grew to $4.4M from $12k at year-end 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":510000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":526677,"accession_number":"0001213900-26-058996","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2026-05-19T20:05:26+00:00","items":["2.02","9.01"],"status":"ready","headline":"Corvex (fka Movano) reports pro forma combined Q1 2026 net loss $15.9M post-merger","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Pro forma combined Q1 2026 revenue $3.65M, net loss $15.93M ($7.81 diluted EPS).","Pro forma FY 2025 revenue $7.54M, net loss $68.40M ($33.53 diluted EPS).","Merger purchase price $581.9M; goodwill $518.3M, intangibles $15.4M (customer rel., trade names).","Consideration includes Series B/C/D convertible preferred shares; conversion contingent on stockholder vote.","Company renamed Corvex effective March 23, 2026; paid stock dividend of 0.358 shares per share on April 6."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95072,"accession_number":"0001213900-26-050668","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K/A","filed_at":"2026-05-01T23:59:59+00:00","items":["9.01","7.01"],"status":"ready","headline":"Corvex Legacy Holdings audited 2025 revenue $7.1M, net loss $9.5M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Audited 2025 revenue of $7.1M; net loss $9.5M driven by $7.1M G&A and $9.6M warrant expense.","Cash and equivalents $35.3M at Dec 31, 2025 vs $3.8M at Dec 31, 2024.","Total assets $67.6M; accumulated deficit $13.8M; SAFE liability $27.3M, warrant liabilities $13.1M.","Pro forma combined financials reflect acquisition by former Movano (now Corvex) closed March 19, 2026.","Three customers represent 67% of 2025 revenue; two suppliers represent 86% of purchases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95074,"accession_number":"0001213900-26-048644","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Corvex dismisses RBSM, appoints BDO as auditor following merger close","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On April 27, 2026, audit committee dismissed RBSM and engaged BDO as auditor for FY 2026.","RBSM's FY 2025 report had a going-concern paragraph; no disagreements except prior material weaknesses.","BDO previously served as auditor of Corvex Legacy Holdings, Inc. before the March 19 merger.","No consulting disagreements or reportable events occurred with BDO prior to engagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95073,"accession_number":"0001213900-26-041734","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Corvex regains Nasdaq minimum equity compliance; subject to one-year monitor","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Panel found Corvex compliant with minimum stockholders' equity as of April 7, 2026.","Company was previously granted an extension to March 30, 2026 to regain compliance.","Corvex placed under one-year Mandatory Panel Monitor starting April 7, 2026.","During monitor, non-compliance results in no plan submission opportunity; only a new hearing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107884,"accession_number":"0001213900-26-031846","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["1.01","5.03","3.01","3.02","3.03","5.02","7.01","9.01"],"status":"ready","headline":"Movano completes reverse merger with Corvex, resolves Nasdaq deficiency, appoints new CEO","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closed merger with Corvex on March 19, 2026; issued convertible preferred shares to Corvex securityholders representing up to 19.9% voting power on as-converted basis.","Stock dividend of 0.358 share per outstanding common share payable April 6, 2026 to holders of record March 30, 2026.","Company regains Nasdaq stockholders' equity requirement compliance with equity >$2.5M post-merger; awaiting formal confirmation.","Jay Crystal appointed CEO (base salary $500K), John Mastrototaro as COO; Michael Leabman and Shaheen Wirk resigned.","Series B Preferred automatically converts to common on March 31, 2026; Series C and D conversion subject to shareholder approval at May 2026 meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124299,"accession_number":"0001213900-25-124005","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Movano republishes FY2024 financials after reverse split; revenue $1.0M, going concern noted","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Revenue of $1.0M in 2024 (first revenue) vs $0 in 2023; net loss $23.7M vs $29.3M.","Accumulated deficit of $148.1M as of Dec 31, 2024; auditor expresses substantial doubt about going concern.","Cash and cash equivalents $7.9M at Dec 31, 2024; negative operating cash flow of $22.5M in 2024.","1-for-10 reverse stock split effective Oct 10, 2025 reduced shares from ~8.3M to ~0.8M; all per-share data restated.","Total operating expenses $25.2M in 2024, down from $29.7M in 2023; R&D spending decreased to $11.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124298,"accession_number":"0001213900-25-122540","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Movano stockholders approve 5x share authorization increase and equity line with Chardan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized shares increased from 500M to 2.5B; issuance of >20% of outstanding shares under ChEF Purchase Agreement approved.","Chardan Capital Markets deal allows Movano to sell up to 20%+ of common stock; 252,589 votes for, 2,088 against.","Amendment No. 3 to 2019 Omnibus Incentive Plan adopted, adding 500,000 shares (total authorized plan shares: 656,000).","All four proposals passed at December 16, 2025 special meeting; adjournment also approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124297,"accession_number":"0001213900-25-107857","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["1.01","2.03","2.01","3.02","5.01","5.03","7.01","9.01"],"status":"ready","headline":"Movano to acquire Corvex in reverse merger; Corvex stockholders to own ~96% of combined company","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Corvex valued at $250M, Movano at $10M; pre-Merger Corvex holders to own ~96.2% of combined entity.","Movano raises $3M via Series A convertible at $5.50/sh; secures $1B equity facility from Chardan.","Corvex concurrently raises $37.1M in private placement; Movano to sell operating assets and distribute proceeds.","Support agreements from 21.2% of Movano shares to vote in favor; directors and officers subject to 180-day lock-up.","Combined company board: 5 Corvex designees, 1 Movano designee; name change to Corvex, Inc. proposed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124296,"accession_number":"0001213900-25-107646","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Movano extends loan maturity to Nov 5, 2025 via amendment with Evie Holdings","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Amendment to Loan Agreement with Evie Holdings LLC dated Nov 3, 2025.","Maturity date extended to November 5, 2025 (only two days from amendment).","Original loan dated Aug 6, 2025; short extension suggests liquidity pressure.","Full terms of amendment to be filed in 10-K for Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124295,"accession_number":"0001213900-25-097241","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2025-10-08T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"Movano Health announces 1-for-10 reverse stock split effective Oct 10, 2025 to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio 1-for-10, effective 12:01 a.m. ET on Oct 10, 2025.","Shares outstanding reduce from ~8.3M to ~0.8M; authorized shares unchanged.","New CUSIP 62459M 305; stock continues trading on Nasdaq under symbol MOVE.","Split intended to regain compliance with Nasdaq minimum bid price requirement.","No fractional shares; stockholders receive cash in lieu of fractional interests."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124293,"accession_number":"0001213900-25-097422","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K/A","filed_at":"2025-10-08T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Movano files 8-K/A to correct Certificate of Amendment; terms unknown","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["This amendment replaces Exhibit 3.1 (Certificate of Amendment) filed with original 8-K on Oct 8, 2025.","Certificate of Amendment effective October 10, 2025; specific changes not disclosed in this filing.","Press release remains unchanged and was previously furnished; no new financial or operational information."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124294,"accession_number":"0001213900-25-096069","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Movano receives Nasdaq delisting notice for equity deficiency","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Reported stockholders' equity of $1.637M as of June 30, 2025, below $2.5M minimum.","Must present compliance plan to Nasdaq Panel by October 8, 2025.","Previously regained compliance with periodic filing rule on Sept 24, 2025.","Stockholders approved reverse stock split on Sept 26 to address bid price rule by Oct 30."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140972,"accession_number":"0001213900-25-092661","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Movano stockholders approve reverse split and authorized share increase to 2B","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Emily Wang Fairbairn (750,312 for) and Michael Leabman (1,030,839 for) as Class I directors.","Approved reverse stock split at ratios 1-for-2 to 1-for-15; board discretion on ratio within 1 year; 4,452,433 for, 489,459 against.","Approved increase in authorized common shares from 500M to 2B; 4,572,312 for, 530,672 against.","Ratified RBSM LLP as independent auditor for 2025; 5,025,298 for, 83,248 against, 43,481 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140971,"accession_number":"0001213900-25-081790","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2025-08-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nasdaq panel grants Movano Health listing extension through Oct 30, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Deadline to file delinquent Q1 and Q2 2025 10-Qs is Sept 30, 2025; bid price compliance by Oct 30, 2025.","Preliminary proxy filed for annual meeting on Sept 26, 2025, seeking reverse stock split approval.","Company working with new auditor to complete the overdue quarterly reports.","Panel hearing held Aug 19, 2025; extension letter received Aug 27, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140970,"accession_number":"0001213900-25-079935","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Movano Health receives Nasdaq deficiency notice for late Q2 10-Q; awaits Panel decision on stay","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notice received Aug 21, 2025 for failure to file Form 10-Q due Aug 14, 2025.","Hearing held Aug 19, 2025; compliance plan submitted covering filing and minimum bid price rules.","New auditor RBSM LLP engaged Aug 13, 2025 as part of compliance plan.","No assurance Panel will grant stay or that Movano can regain compliance and maintain listing.","Stock ticker MOVE trades on Nasdaq Capital Market; risk of suspension if Panel denies request."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140969,"accession_number":"0001213900-25-077062","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"Movano Inc. appoints RBSM LLP as new independent auditor for FY 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Audit Committee approved engagement of RBSM LLP on August 13, 2025.","RBSM replaces prior auditor for fiscal year ending December 31, 2025 and interim periods.","No consultations with RBSM on accounting principles or audit opinions during 2023, 2024, or interim.","No disagreements or reportable events (as defined in Regulation S‑K Item 304) occurred."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140968,"accession_number":"0001213900-25-073070","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Movano secures $1.5M bridge loan at 12% interest to fund strategic alternatives","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$1.5M bridge loan with 12% annual interest, maturing November 4, 2025.","Proceeds to continue pursuit of strategic alternatives as disclosed in May 2025 8-K.","Lender receives security interest in all assets, including intellectual property.","Loan includes provision that could double outstanding principal upon certain trigger events.","Maturity may be extended up to 60 days if definitive documentation for a Qualifying Transaction is executed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140967,"accession_number":"0001213900-25-063354","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2025-07-11T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Movano receives Nasdaq delisting notice; plans to appeal by July 14, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Movano on July 7, 2025, that its common stock fails the $1.00 minimum bid price and late filing requirements.","Company has effected a reverse stock split in the prior year, making it ineligible for a standard compliance period.","Trading suspension scheduled for July 16, 2025, unless Nasdaq hearings panel grants an extended stay.","Movano intends to request a hearing and an extended stay, but there is no assurance of relief.","Delisting would materially impair ability to raise capital and adversely affect financial condition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158735,"accession_number":"0001213900-25-057891","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Movano's auditor Moss Adams resigns; prior reports had going concern uncertainty","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Auditor Moss Adams LLP resigned effective June 24, 2025, following Movano's exploration of strategic alternatives.","Moss Adams' audit reports for FY2023 and FY2024 included an explanatory paragraph about going concern uncertainty.","No disagreements but company disclosed material weaknesses in internal controls in prior 10-Ks (control environment, IT general controls, financial close).","No new auditor named; board initiated strategic alternatives process in May 2025, including potential sale or merger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158734,"accession_number":"0001213900-25-047333","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Movano receives Nasdaq deficiency notice for late Q1 10-Q; 60 days to submit plan","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on May 20, 2025 for missing May 15 deadline to file Q1 2025 Form 10-Q.","Must submit a compliance plan by July 21, 2025; if accepted, Nasdaq may grant extension to Nov 11, 2025.","If plan rejected, company can appeal to a Nasdaq Hearings Panel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158733,"accession_number":"0001213900-25-045106","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"Movano explores strategic alternatives, delays Q1 10-Q filing due to cash constraints","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board initiated process to explore strategic alternatives including sale or merger; engaged Aquilo Partners and K&L Gates.","Company will not timely file Q1 2025 10-Q due to resource constraints.","Estimated cash $4.3M, accounts payable $2.5M, total assets $7.8M as of March 31, 2025.","No assurance of any transaction; further disclosure only upon Board approval of a specific course."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177138,"accession_number":"0001213900-25-000411","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2025-01-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Appoints Shaheen Wirk as Class III director and Audit Committee member","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Shaheen Wirk appointed to Board as Class III director, term through 2027 annual meeting.","Wirk will serve on Audit Committee of the Board.","Granted options to purchase 13,300 shares under 2019 Omnibus Incentive Plan.","Will also receive annual option award of 10,000 shares per Non-Employee Director Compensation Policy.","No material interests or arrangements triggering Item 404(a) disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193916,"accession_number":"0001213900-24-098462","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Movano Health reports Q3 operating loss $7.4M, ships 339 Evie Rings, reverse split completed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Operating loss of $7.4M in Q3 2024, improved from $9.1M loss in Q3 2023.","Cash and equivalents at Sept 30, 2024: $11.3M.","1-for-15 reverse stock split executed Oct 29; Nasdaq bid price compliance regained Nov 12.","EvieMED 510(k) review in final stage; complete response submitted late Oct for medical features.","Entered agreement phase for Q1 2025 pilot program with large healthcare company using EvieMED."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":902000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193915,"accession_number":"0001213900-24-090544","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2024-10-25T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"Movano Health to effect 1-for-15 reverse stock split on Oct 29 to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio 1-for-15; shares outstanding will fall from ~99.5M to ~6.6M.","Effective 12:01 a.m. ET Oct 29, 2024; stock will trade split-adjusted on Nasdaq under unchanged ticker MOVE.","Fractional shares rounded up to next whole share; authorized shares and par value unchanged.","Split intended to raise bid price to meet Nasdaq minimum bid price listing requirement.","New CUSIP 62459M206; board determined ratio after shareholder authorization on July 9, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210242,"accession_number":"0001213900-24-069021","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Movano Health Q2 2024 operating loss narrows to $6.4M; Evie Ring back in stock Sept 17","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Operating loss of $6.4M improved from $7.4M in Q2 2023; no revenue reported as refunds offset deferred revenue.","Shipped 1,837 Evie Rings in Q2; cash and equivalents $16.9M at June 30, 2024.","Evie Ring expected back in stock September 17, 2024; brand partnership with Heidi D'Amelio announced.","FDA live meeting scheduled mid-August for EvieMED 510(k) clearance; B2B opportunities with pharma and payor advancing.","April 2024 $24.1M private placement closed with tier-1 medical device company investment."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":852000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210241,"accession_number":"0001213900-24-060520","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2024-07-10T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Movano shareholders approve increase in authorized shares from 150M to 500M and reverse stock split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved certificate amendment increasing authorized common shares from 150,000,000 to 500,000,000.","Stockholders authorized a reverse stock split at ratio between 1-for-2 and 1-for-30, at Board discretion within one year.","Stockholders approved Amendment No. 2 to 2019 Omnibus Incentive Plan, adding 10,000,000 shares.","Stockholders elected Brian Cullinan as Class III director with 28,986,938 votes for.","Stockholders ratified appointment of Moss Adams LLP as independent auditor for 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228533,"accession_number":"0001213900-24-047533","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2024-05-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Movano replaces B. Riley with JonesTrading as ATM sales agent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment adds JonesTrading as sales agent and removes B. Riley from existing At Market Issuance Agreement dated Aug 15, 2022.","No changes to terms other than agent substitution; all other provisions remain in effect.","B. Riley's rights and obligations under the agreement terminate, except Section 9 (indemnification) survives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228532,"accession_number":"0001213900-24-043664","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Movano Health reports Q1 revenue $852k, operating loss $5.8M; closes $24M private placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 revenue $852,000 from 5,305 Evie Rings shipped; operating loss $5.8M vs $7.2M a year ago.","Closed $24.1M private placement on April 4, 2024, including investment from a tier-1 medical device company.","FDA 510(k) decision for Evie Med Ring pulse oximeter expected July 2024; SpO2 trial RMSE 2.46% (below 3.5% FDA guidance).","Planning arterial blood pressure study in June using arterial line for continuous data.","Cash and cash equivalents $2.1M at March 31, 2024; D2C orders paused pending improvements."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":852000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228531,"accession_number":"0001213900-24-030443","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2024-04-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Movano Health raises $24M, reports Q4 operating loss of $6.0M, achieves FDA accuracy milestone","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Executed $24M private placement including $3.0M from a tier-1 medical device company and $3.6M from insiders.","Q4 2023 operating loss of $6.0M, improved from $8.0M loss in Q4 2022.","Second hypoxia trial: Evie Ring pulse oximeter RMSE 2.46% (FDA guideline 3.5%), exceeding two hospital-grade reference devices.","Ended 2023 with $6.1M cash; new financing extends runway for Evie Med FDA submission and B2B strategy.","Launched Evie Ring in Nov 2023; revenue recognition begins in 2024 as shipments started Jan 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228530,"accession_number":"0001213900-24-029886","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2024-04-03T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Movano raises ~$24.2M in private placement of units with warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised ~$24.2M gross via 45.3M units at $0.533/unit (directors/officers at $0.565/unit).","Each unit includes one share (or pre-funded warrant) plus one warrant exercisable at $0.4071 for 5 years.","Up to ~$18.4M additional gross proceeds if all warrants exercised for cash.","Net proceeds to fund working capital and general corporate purposes; closing expected April 4, 2024.","Directors and officers purchased 331,856 units at $0.565/unit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264636,"accession_number":"0001213900-23-090755","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2023-11-29T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Movano Health reports over $1M in Evie Ring orders; cuffless BP tech passes FDA accuracy standard","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Over $1M in orders during Black Friday holiday launch of Evie Ring smart ring for women.","Cuffless blood pressure prototype achieved MAD of 5.9 mmHg, below IEEE1708a-2019 standard of 7 mmHg.","Company holds 23 issued and 31 pending patents on mmWave RF and AI technology.","Expects cash burn rate to reduce by approximately 40% in 2024 as pipeline advances.","Progress in non-invasive glucose monitoring, skin color agnostic, high-fidelity data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264635,"accession_number":"0001213900-23-088348","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2023-11-17T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Movano receives Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notice dated Nov 14, 2023: common stock bid price below $1.00 for 30 consecutive days.","Company has 180 days until May 13, 2024 to regain compliance by closing at $1.00+ for 10 consecutive days.","If non-compliant by May 13, 2024, may seek a second 180-day grace period if other listing standards met.","Failure to regain compliance could lead to delisting from Nasdaq Capital Market.","Management evaluating actions to cure deficiency; no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264634,"accession_number":"0001213900-23-087246","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2023-11-15T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Movano Health prices $3.6M public offering of 4.2M shares at $0.85/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 4,235,304 shares of common stock at $0.85 per share, gross proceeds of $3.6M.","Underwriter granted 30-day option to purchase up to 635,296 additional shares (15% of offering).","Net proceeds to be used for general corporate purposes, including product development and commercialization.","Closing expected on or about November 17, 2023, subject to customary conditions.","The Benchmark Company, LLC acted as sole book-running manager for the offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264633,"accession_number":"0001213900-23-087243","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2023-11-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Movano Health to launch Evie Ring Nov 20; reports Q3 net loss $9.0M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Evie Ring launches Nov 20 at $269 with no subscription; shipping expected by year-end.","Blood pressure SoC met FDA accuracy standards in clinical study; pivotal trial planned.","FDA requested additional info on Evie Ring pulse oximeter 510(k); reply planned Q1 2024.","Priced $3.6M public offering of 4.2M shares at $0.85; expected close Nov 17.","Q3 net loss $9.0M ($0.18 loss per share); no revenue; pro forma cash $10.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281872,"accession_number":"0001213900-23-067081","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Movano Health reports Q2 net loss $7.3M; Evie Ring launch planned before Black Friday 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $7.3M ($0.17 per share) vs $6.9M loss ($0.21 per share) in Q2 2022; no revenue.","Cash $14.5M at June 30, 2023, up from $10.8M at year-end 2022; raised $9.2M in public offering.","FDA 510(k) for Evie Ring pulse oximeter under full review; launch expected before Black Friday 2023.","Over 600,000 website visitors YTD and 100,000 sign-ups for Evie Ring updates.","Beta partners include global athletic apparel, major health insurer, and remote patient monitoring company."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300863,"accession_number":"0001213900-23-050498","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2023-06-21T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Movano Inc. doubles authorized shares to 150M; stockholders approve at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed Certificate of Amendment increasing authorized common stock from 75M to 150M shares, effective June 21, 2023.","Share increase approved by stockholders with 20.77M votes in favor, 1.16M against, 0.57M abstain.","Elected Class II directors John Mastrototaro and Rubén Caballero; ratified Moss Adams as auditor for 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300862,"accession_number":"0001213900-23-048353","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2023-06-13T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Movano Health prices $8.0M public offering of 8M shares at $1.00 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $8.0M from offering of 8,000,000 shares at $1.00/share.","Underwriter granted 30-day option to purchase up to additional 1.2M shares (15%).","Offering expected to close June 15, 2023; net proceeds for product development and commercialization.","Benchmark Company, LLC acting as sole book-running manager.","Shares offered under previously effective S-3 shelf registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300861,"accession_number":"0001213900-23-039342","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Movano Health Q1 2023 net loss $7.1M; Evie Ring launch planned September at $269","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.1M ($0.19 per share) in Q1 2023 vs $6.9M loss in Q1 2022; no revenue generated.","Evie Ring to launch September 2023 at $269 with no subscription; 510(k) submission for heart rate/SpO2 expected June 2023.","Over 80,000 sign-ups and nearly 500,000 website visits since Evie Ring announcement at CES in January 2023.","Completed first beta programs with four partners; second beta round by early July includes global athletic apparel company.","Completed blood pressure clinical trial with 50+ subjects using proprietary RF single-chip solution; glucose trial planned."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320768,"accession_number":"0001213900-23-021242","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2023-03-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Movano Health Q4 2022 net loss $7.9M; progressing toward summer 2023 Evie Ring launch","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.9M ($0.24/sh) in Q4 2022 vs $6.3M ($0.19/sh) in Q4 2021; no revenue in either period.","Cash and equivalents $10.8M at Dec 31, 2022; completed $7.5M public offering in Q1 2023.","Evie Ring on track for summer 2023 launch; second beta program with global athletic apparel and medical device firms.","Plan to file first 510(k) for heart rate and SpO2 clearance this spring after successful hypoxia trial (2% SpO2 margin of error).","Issued 9 new U.S. patents (21 total) for non-invasive blood pressure and glucose monitoring; first clinical studies imminent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320767,"accession_number":"0001213900-23-006456","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2023-01-31T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Movano raises $5.8M in underwritten public offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offered 4,644,000 shares at $1.40 each plus one warrant per two shares.","Warrants exercisable at $1.57/share, expire in 5 years; redeemable by company if stock ≥$4.87 for 10 days.","Net proceeds ~$5.8M after underwriting discounts; will fund product development and commercialization.","Offering closed Jan 31, 2023; Newbridge Securities acted as sole book-runner.","Warrants will not be listed on any exchange; no trading market expected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338899,"accession_number":"0001213900-22-072330","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Movano Health reports Q3 net loss of $8.6M; progress on FDA submission and beta programs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $8.6M ($0.26 diluted EPS) vs $5.2M ($0.16) in Q3 2021; no revenue.","Cash and short-term investments $16.8M at Sept 30, down from $33.6M at Dec 31, 2021.","Raised $1.9M via ATM facility in Q3; 33.5M shares outstanding.","Plans to file for FDA clearance for heart rate and SpO2 in early 2023 after pivotal hypoxia study.","Beta programs underway with Novant Health, Stanford, and two other partners; product launch expected H1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356269,"accession_number":"0001213900-22-048144","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2022-08-15T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Movano Q2 net loss $6.9M; advances Ring beta tests, hypoxia study meets FDA SpO2 accuracy","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $6.9M ($0.21/sh) vs $4.7M ($0.15/sh) in Q2 2021; no revenue as development-stage company.","Cash $21.3M at June 30, 2022, down from $33.6M at Dec 31, 2021.","Plans DTC launch of Movano Ring in H1 2023; beta partners include Stanford, major pharma, diabetes device firm.","Hypoxia study with UCSF: Ring achieved 2% SpO2 error margin (FDA requires 4%); larger pivotal study planned.","Two new patents granted for SoC; planning BP and glucose clinical studies in Q3 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374646,"accession_number":"0001213900-22-034332","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2022-06-22T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Movano stockholders approve 6M share increase to 2019 Omnibus Incentive Plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No. 1 approved with 7,027,397 for, 718,084 against, 471,024 abstain, and 10,561,143 broker non-votes.","Authorized shares under the plan increased from 7,400,000 to 13,400,000.","Stockholders elected Emily Wang Fairbairn (7,222,473 for) and Michael Leabman (7,784,479 for) as Class I directors for three-year terms.","Ratification of Moss Adams LLP as independent auditor for 2022 passed with 18,261,610 for, 103,028 against, 413,010 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374645,"accession_number":"0001213900-22-025983","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2022-05-12T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Movano Q1 net loss $6.9M; validates SoC for glucose, BP; beta on track for 2H 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.9M ($0.21/share) vs $8.1M ($1.01/share) in Q1 2021; operating loss $6.9M.","Cash and investments $27.7M as of Mar 31, 2022, down from $33.6M at Dec 31, 2021.","Validated proprietary mmWave SoC for non-invasive glucose and cuffless blood pressure monitoring.","Hired go-to-market leadership team; added Nan Kirsten Forte to Board; plans limited beta release in 2H 2022.","No revenue generated; company remains development stage with R&D focus."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374644,"accession_number":"0001213900-22-020398","cik":1734750,"company_name":"Corvex, Inc.","ticker":"MOVE","form_type":"8-K","filed_at":"2022-04-18T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Movano appoints Nan Kirsten Forte to board, expands board to six","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from five to six; Forte appointed as Class III director until 2024 annual meeting.","Forte granted options to purchase 420,000 shares under 2019 Omnibus Incentive Plan.","Forte will chair the newly established Corporate Development Committee.","Forte is EVP & GM of Everyday Health Group at Ziff Davis (ZD), bringing digital health experience.","Movano expects beta release of Movano Ring in second half of 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":42245827.490800366,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-04-18T23:59:59+00:00|374644"}